GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Warfarin sodium - oral

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Warfarin tablets - INR-guided dosing with renal monitoring

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
INR-guided; no fixed CrCl/eGFR adjustment table.

Dosing / renal protocol and limits

When CYP2C9/VKORC1 genotypes are not known, the label describes an initial 2-5 mg orally once daily and typical maintenance of 2-10 mg daily. These are orientation ranges, not a fixed prescription: select the dose by indication, INR response, interacting drugs and patient factors.

The label does not mandate an automatic renal reduction. Patients with renal impairment should have more frequent INR monitoring. Serious or fatal bleeding is the boxed warning; anticoagulant-related nephropathy is also relevant. A stable renal classification does not establish a stable warfarin dose.

Source revision: DailyMed updated 2025-10-07. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e742c8-0768-4704-8871-708c27daa65b

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Warfarin tablets - INR-guided dosing with renal monitoring

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: INR-guided; no fixed CrCl/eGFR adjustment table.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Jantoven

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Adult product-specific renal information; not a complete prescribing regimen.

Renal method: INR-guided dosing; no numeric renal-function dose bands.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - JANTOVEN

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Oral warfarin sodium; renal and INR monitoring comments, not a complete anticoagulation protocol.

Renal method: Clinical renal impairment; INR-guided dosing rather than a CrCl/eGFR dose band.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Warfarin sodium

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Handbook source

Renal Drug Handbook, 5th edition - Warfarin sodium

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeWarfarin tablets - INR-guided dosing with renal monitoringGlobalRPh RX List - JantovenGlobalRPh RX List - JANTOVENRenal Drug Handbook, 5th edition - Warfarin sodium
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e742c8-0768-4704-8871-708c27daa65b

Product and population scope

Adult Warfarin sodium - oral. Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-warfarin · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Warfarin tablets - INR-guided dosing with renal monitoring

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: INR-guided; no fixed CrCl/eGFR adjustment table.
Source date: DailyMed updated 2025-10-07.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

When CYP2C9/VKORC1 genotypes are not known, the label describes an initial 2-5 mg orally once daily and typical maintenance of 2-10 mg daily. These are orientation ranges, not a fixed prescription: select the dose by indication, INR response, interacting drugs and patient factors.

The label does not mandate an automatic renal reduction. Patients with renal impairment should have more frequent INR monitoring. Serious or fatal bleeding is the boxed warning; anticoagulant-related nephropathy is also relevant. A stable renal classification does not establish a stable warfarin dose.

RDM30-090-warfarin-1 · Source locator: Warfarin tablets - INR-guided dosing with renal monitoring; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e742c8-0768-4704-8871-708c27daa65b
Retrieved
2026-09-05
DailyMed Set ID
b0e742c8-0768-4704-8871-708c27daa65b
Renal-function method
INR-guided; no fixed CrCl/eGFR adjustment table.
Source date/version
DailyMed updated 2025-10-07.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
65829bc1e0a5204c89cb01df7eb2c08d8c10ba291e0d6a1b27a6f927a05e118a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Jantoven

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult product-specific renal information; not a complete prescribing regimen.

Renal method: INR-guided dosing; no numeric renal-function dose bands.
Source date: September 2017 on retrieved RX page
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The JANTOVEN source does not require an automatic renal-failure dose reduction, but requires more frequent INR monitoring with compromised renal function. Dose and target INR remain individualized to response and indication. This is not a fixed-dose recommendation or a statement that kidney disease carries no bleeding risk.

RDM34-rxlist-jantoven-drug-C1 · Source locator: Dosage and administration: individualized dosing and renal impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/jantoven-drug/
Retrieved
2026-09-07
Renal-function method
INR-guided dosing; no numeric renal-function dose bands.
Source date/version
September 2017 on retrieved RX page
Hash meaning
SHA-256 of local authored summary only, not original HTML, PDF or SPL bytes.
Local summary SHA-256
8d375ccd17cd09bf39dd55df27cca642af263f7ada5eb2e166d5338eec97336a
Rxlist

GlobalRPh RX List - JANTOVEN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Oral warfarin sodium; renal and INR monitoring comments, not a complete anticoagulation protocol.

Renal method: Clinical renal impairment; INR-guided dosing rather than a CrCl/eGFR dose band.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The label does not require a fixed renal dose adjustment, including renal failure. Warfarin remains titrated to the indication-specific INR; renal impairment calls for more frequent INR assessment and adds bleeding risk. A no-fixed-adjustment statement is not permission to use a standard dose without INR-guided individualization. No dialysis-specific fixed dose is supplied by this excerpt.

RDM36-rxlist-warfarin-6bb2d2573c-C1 · Source locator: Dosage: Renal Impairment; Use in Specific Populations; bleeding risk factors.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/jantoven-drug/
Retrieved
2026-09-07
Renal-function method
Clinical renal impairment; INR-guided dosing rather than a CrCl/eGFR dose band.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
92eca77ff26b92bf5bc9c7afb119bdb3123d96035dc077193727b3d4667be3df
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Warfarin sodium

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. Here usual dosing means INR-guided individualization, not a fixed renal dose. HD/PD/continuous removal is described as absent; high-flux removal unknown. The book notes reduced protein binding with renal impairment. Current U.S. label monitoring and bleeding/nephropathy precautions remain separate.

HB30-warfarin-1 · Source locator: Printed page 1073: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 1073; uploaded PDF p. 1092
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e742c8-0768-4704-8871-708c27daa65b
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
696a6dbed13e5f639ebd73f02470d4ec2d6d2fe1460a456bc3c6719cf86cee91

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e742c8-0768-4704-8871-708c27daa65b
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
d00d3390902bf83b74424ed0477206d338c4aff13fa4ee246f8d5afb092b7e66
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report